Federal Register / Vol. 75, No. 35 / Tuesday, February 23, 2010 / Notices 8085 

Dated: February 16, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–3455 Filed 2–22–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Barrett’s Esophagus. 

Date: March 12, 2010. 

Time: 3:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Maria E. Davila-Bloom, 

PhD, Scientific Review Officer, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 758, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

594–7637, davilabloomm@extra.niddk.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK Ancillary 

R01 Application Review. 

Date: March 19, 2010. 

Time: 10:30 a.m. to 11:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Xiaodu Guo, MD, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 761, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–4719, 

guox@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: February 16, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–3456 Filed 2–22–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Research Program Project in Cardiac 

Fibrillation. 

Date: March 2, 2010. 

Time: 10 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: William J Johnson, PhD, 

Scientific Review Officer, Review Branch/ 

DERA, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, Room 7178, 

Bethesda, MD 20892–7924, 301–435–0725 

johnsonwj@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Randomized Evaluation of VAD InterVEntion 

before Inotropic Therapy (REVIVE–IT) 

Date: March 3, 2010. 

Time: 10 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: YingYing Li-Smerin, PhD, 

MD, Scientific Review Officer, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7184, Bethesda, MD 20892–7924, 301–435– 

0277, lismerin@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: February 16, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–3457 Filed 2–22–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institutes of Health Guidelines 

for Human Stem Cell Research 

SUMMARY: The National Institutes of 

Health (NIH) is requesting public 

comment on a revision to the definition 

of human embryonic stem cells (hESCs) 

in the ‘‘National Institutes of Health 

Guidelines for Human Stem Cell 

Research’’ (Guidelines). 

On July 7, 2009, NIH issued 

Guidelines (http:// 

edocket.access.gpo.gov/2009/pdf/E9- 

15954.pdf) to implement Executive 

Order 13505, as it pertains to NIHfunded stem cell research, to establish 

policy and procedures under which the 

NIH will fund such research, and help 

ensure that NIH-funded research in this 

area is ethically responsible, 

scientifically worthy, and conducted in 

accordance with applicable law. 

In Section II of the final Guidelines, 

hESCs are defined as: ‘‘For the purpose 

of these Guidelines, ‘human embryonic 

stem cells (hESCs)’ are cells that are 

derived from the inner cell mass of 

blastocyst stage human embryos, are 

capable of dividing without 

differentiating for a prolonged period in 

culture, and are known to develop into 

cells and tissues of the three primary 

germ layers.’’ 

This definition had the unintended 

consequence of excluding certain hESCs 

which may otherwise be appropriate for 

Federal funding. For example, the 

current definition excludes hESCs from 

an embryo which fails to develop to the 

blastocyst stage. 

Therefore, the NIH proposes replacing 

the current definition of hESCs in 

Section II with the following: ‘‘For the 

purpose of these Guidelines, ‘human 

embryonic stem cells (hESCs)’ are 

pluripotent cells that are derived from 

mstockstill on DSKH9S0YB1PROD with NOTICES